Charles River Laboratories PE Ratio 2010-2025 | CRL
Current and historical p/e ratio for Charles River Laboratories (CRL) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Charles River Laboratories PE ratio as of July 21, 2025 is 14.42.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Charles River Laboratories PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-07-22 | 163.36 | 0.00 | |
| 2025-03-31 | 150.52 | $-0.65 | 0.00 |
| 2024-12-31 | 184.60 | $0.15 | 1230.67 |
| 2024-09-30 | 196.97 | $7.99 | 24.65 |
| 2024-06-30 | 206.58 | $8.35 | 24.74 |
| 2024-03-31 | 270.95 | $8.50 | 31.88 |
| 2023-12-31 | 236.40 | $9.21 | 25.67 |
| 2023-09-30 | 195.98 | $9.24 | 21.21 |
| 2023-06-30 | 210.25 | $9.43 | 22.30 |
| 2023-03-31 | 201.82 | $9.67 | 20.87 |
| 2022-12-31 | 217.90 | $9.47 | 23.01 |
| 2022-09-30 | 196.80 | $8.49 | 23.18 |
| 2022-06-30 | 213.97 | $8.62 | 24.82 |
| 2022-03-31 | 283.97 | $8.21 | 34.59 |
| 2021-12-31 | 376.78 | $7.60 | 49.58 |
| 2021-09-30 | 412.67 | $7.74 | 53.32 |
| 2021-06-30 | 369.92 | $7.76 | 47.67 |
| 2021-03-31 | 289.83 | $7.38 | 39.27 |
| 2020-12-31 | 249.86 | $7.20 | 34.70 |
| 2020-09-30 | 226.45 | $6.00 | 37.74 |
| 2020-06-30 | 174.35 | $5.43 | 32.11 |
| 2020-03-31 | 126.21 | $4.97 | 25.39 |
| 2019-12-31 | 152.76 | $5.06 | 30.19 |
| 2019-09-30 | 132.37 | $4.66 | 28.41 |
| 2019-06-30 | 141.90 | $4.42 | 32.10 |
| 2019-03-31 | 145.25 | $4.64 | 31.30 |
| 2018-12-31 | 113.18 | $4.61 | 24.55 |
| 2018-09-30 | 134.54 | $2.77 | 48.57 |
| 2018-06-30 | 112.26 | $2.63 | 42.68 |
| 2018-03-31 | 106.74 | $2.65 | 40.28 |
| 2017-12-31 | 109.45 | $2.54 | 43.09 |
| 2017-09-30 | 108.02 | $4.10 | 26.35 |
| 2017-06-30 | 101.15 | $3.81 | 26.55 |
| 2017-03-31 | 89.95 | $3.42 | 26.30 |
| 2016-12-31 | 76.19 | $3.23 | 23.59 |
| 2016-09-30 | 83.34 | $2.97 | 28.06 |
| 2016-06-30 | 82.44 | $2.97 | 27.76 |
| 2016-03-31 | 75.94 | $3.26 | 23.29 |
| 2015-12-31 | 80.39 | $3.14 | 25.60 |
| 2015-09-30 | 63.52 | $3.04 | 20.89 |
| 2015-06-30 | 70.34 | $2.93 | 24.01 |
| 2015-03-31 | 79.29 | $2.65 | 29.92 |
| 2014-12-31 | 63.64 | $2.66 | 23.92 |
| 2014-09-30 | 59.74 | $2.49 | 23.99 |
| 2014-06-30 | 53.52 | $2.45 | 21.84 |
| 2014-03-31 | 60.34 | $2.27 | 26.58 |
| 2013-12-31 | 53.04 | $2.13 | 24.90 |
| 2013-09-30 | 46.26 | $2.11 | 21.92 |
| 2013-06-30 | 41.03 | $1.93 | 21.26 |
| 2013-03-31 | 44.27 | $2.00 | 22.14 |
| 2012-12-31 | 37.47 | $2.01 | 18.64 |
| 2012-09-30 | 39.60 | $2.18 | 18.17 |
| 2012-06-30 | 32.76 | $2.09 | 15.67 |
| 2012-03-31 | 36.09 | $2.09 | 17.27 |
| 2011-12-31 | 27.33 | $2.12 | 12.89 |
| 2011-09-30 | 28.62 | $-4.47 | 0.00 |
| 2011-06-30 | 40.65 | $-5.24 | 0.00 |
| 2011-03-31 | 38.38 | $-5.65 | 0.00 |
| 2010-12-31 | 35.54 | $-5.96 | 0.00 |
| 2010-09-30 | 33.15 | $0.35 | 94.71 |
| 2010-06-30 | 34.21 | $1.32 | 25.92 |
| 2010-03-31 | 39.31 | $1.62 | 24.27 |
| 2009-12-31 | 33.69 | $1.74 | 19.36 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $7.357B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.596B | 25.24 |
| CVS Health (CVS) | United States | $77.976B | 9.69 |
| Elevance Health (ELV) | United States | $62.251B | 8.37 |
| Cencora (COR) | United States | $56.726B | 19.74 |
| DiDi Global (DIDIY) | China | $26.168B | 27.80 |
| Labcorp Holdings (LH) | United States | $20.342B | 16.50 |
| Natera (NTRA) | United States | $19.203B | 0.00 |
| BioMerieux (BMXMF) | France | $16.276B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.895B | 0.00 |
| CochLear (CHEOY) | Australia | $13.050B | 0.00 |
| Solventum (SOLV) | United States | $12.516B | 13.25 |
| ICON (ICLR) | Ireland | $11.276B | 10.48 |
| Revvity (RVTY) | United States | $10.693B | 18.40 |
| Viatris (VTRS) | United States | $10.446B | 3.59 |
| Medpace Holdings (MEDP) | United States | $8.878B | 22.97 |
| Sonic Healthcare (SKHHY) | Australia | $8.792B | 0.00 |
| Avantor (AVTR) | United States | $8.409B | 12.22 |
| HealthEquity (HQY) | United States | $8.395B | 36.77 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.197B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.928B | 29.02 |
| BrightSpring Health Services (BTSG) | United States | $3.465B | 31.79 |
| Sotera Health (SHC) | United States | $3.125B | 17.76 |
| Surgery Partners (SGRY) | United States | $2.866B | 37.27 |
| Concentras Parent (CON) | United States | $2.557B | 14.78 |
| Alignment Healthcare (ALHC) | United States | $2.473B | 0.00 |
| Organon (OGN) | United States | $2.457B | 2.61 |
| GeneDx Holdings (WGS) | United States | $2.235B | 86.09 |
| Progyny (PGNY) | United States | $1.966B | 43.28 |
| PACS (PACS) | United States | $1.771B | 0.00 |
| Premier (PINC) | United States | $1.723B | 13.08 |
| GoodRx Holdings (GDRX) | United States | $1.697B | 33.93 |
| Ardent Health (ARDT) | United States | $1.566B | 6.68 |
| Teladoc Health (TDOC) | United States | $1.461B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.232B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.086B | 8.26 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.886B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.846B | 290.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.711B | 6.66 |
| CareDx (CDNA) | United States | $0.710B | 11.09 |
| Nutex Health (NUTX) | United States | $0.618B | 9.35 |
| Embecta (EMBC) | United States | $0.601B | 4.05 |
| So-Young (SY) | China | $0.581B | 0.00 |
| SBC Medicals (SBC) | United States | $0.541B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.513B | 0.00 |
| LifeMD (LFMD) | United States | $0.474B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.470B | 10.58 |
| Sonida Senior Living (SNDA) | United States | $0.468B | 0.00 |
| Omada Health (OMDA) | $0.466B | 0.00 | |
| COMPASS Pathways (CMPS) | United Kingdom | $0.417B | 0.00 |
| Enhabit (EHAB) | United States | $0.340B | 28.00 |
| Oncology Institute (TOI) | United States | $0.304B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.295B | 0.00 |
| Beauty Health (SKIN) | United States | $0.209B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.149B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| Sera Prognostics (SERA) | United States | $0.110B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.081B | 0.00 |
| KindlyMD (NAKA) | United States | $0.066B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.060B | 0.00 |
| Biodesix (BDSX) | United States | $0.051B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.045B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.043B | 0.00 |
| ModivCare (MODV) | United States | $0.042B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.021B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.014B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.007B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |